bionaturis

Biotechnology strengthens its position in Spain

The sales in the sector of the so-called Bioeconomy, has grown from 2.98% GDP (PIB in Spanish) in 2008 to 7.8% in 2012, according to the Asebio report, recently published. Companies stating that biotechnology is their main or only activity –among which Bionaturis is- registered an increase of 10.78% in their sales (8,800 million Euros) and 5% of rise in net employment during 2012, surpassing its own expectations for a year that it has been forecasted very complicated for Spanish economy.

According to Bionaturis’ CEO, Victor Infante, who attended the ASEBIO gala , “apart from the figures that prove that the biotech sector has performed better than others at this time of recession, I´d like to stand out some words heard today such as the need of innovation in all fields, including the relationship with public administrations, patients associations, regulatory authorities, partners at the value chain, with the main goal of seeking sustainability of the health system as a whole; or those promoting to seek talent wherever it is”.

More internationalization

85% of Asebio’s members conducted some international activity in 2013, as Bionaturis did. For the first time since this survey has been done, the associated companies consider LATAM as one of their priority market in their international strategy, specially Mexico (96.67%) and Colombia (95.83%). The European Union (93.24%), Switzerland (90.48%) and USA (88.41%) keep on having a leadership position for international operations.

During 2013, 57 companies and Spanish Organizations from the biotechnological sector (+39% regarding to 2012) signed a total of 108 international business partnerships (+42%).

August 1st, 2014|Blog english|0 Comments|

“We make possible that innovation reaches more people”

Bionaturis’ CEO and founder, Victor Infante, took part last week in the programme Emprende, by RTVE (24 hours channel), with the journalist Juanma Romero and the branding expert, Maria Millan. The manager stated during the interview: “We bring fresh air to the sector making possible that innovation in biotechnology reaches to most people”.

The business and financial strength of the company, with innovation as a cornerstone for its internationalization plan, are some of the remarkable topics in the interview: “We are making history”.

If you haven’t watch the interview yet, please click here (only in Spanish)

Emprende – 17/07/14

July 25th, 2014|Blog english|0 Comments|

July Newsletter

If you want to know Bionaturis’ latests news, here you are our July newsletter

 

IN THIS ISSUE

Juan Juarez buys 5% of Bionaturis and Rafael Contreras increases his position
Bionaturis develops a breakthrough drug for livestock
Bionaturis Group enhances its international alliances in San Diego (USA)
Bionaturis shares start quoting in the continuous system on the MAB

Let’s get to know…

Cristina Infante Viñolo, 33 years old, born in La Linea de la Concepcion, degree in Chemistry at Cadiz University.
 

 

-When you were a child, what did you want to be as an adult?
A pediatrician or a veterinary surgeon.
-What do you like the most about your job?
Thinking that our job is able to improve somenone’s life in the future.
-What are your future challenges?
Rising my daughter Julia.
-Your favourite dish
A sandwich from the Brighton in the beach with my partner.
-A place
The sunrise of the Levante beach in La Linea de la Concepcion.
-A film
“The best youth”, by Marco Tullio Giordana.
-A historical figure
Any women who has fought for her freedom.
-A book
‘The bad girl’, by Mario Vargas Llosa.
-A song
‘Qué sabe nadie’, by Raphael.
-What do you usually do in your free time?
Enjoying of my little great family.
-A proposal to get rid of the crisis
Education and civil responsability, it is necessary a change of mentality about the concept of the State, where we are and how we are contributing inside this State, keeping always the respect and the neighbor’s well-being in mind. I think is as easy as everybody have lost the respect to the rest.
-How do you imagine the world in 20 years?
With social equality, 0% unemployment and without gender violence. That is how I want to imagine it.

  Cristina has been working in Bionturis since December 2008 as a Technician of Technological Development.

Juan Juarez buys 5% […]

Juan Juarez buys 5% of Bionaturis and Rafael Contreras increases his position

The strong Bionaturis (BNT. MC) commitment of consolidating its international growth strategy, presence and professionalization in the financial markets has become real with the appointment of Juan Juarez as a Board Member since last June, 30. As part of the operation, Juarez has acquired 5% of the biotech.

Juan Juarez, degree in Laws at Madrid University and in Economics at Madrid-ICADE, Master in Finance from the IE (Madrid) and Master in Financial Markets (Madrid Stock Exchange), besides of being part of management teams in banks and financial entities, is nowadays an executive and founding partner of companies as Privat und Handel Bank Zürich AG, Ad-Hoc Aesores EAFI SA and Juarez & Asociados –Family Office SA. Juarez is also member of the Board of Directors and financial vice-president at Carbures Group and he is considered a key person in the outstanding growth of the company of composite structures, that has already announced its goal of start quoting soon in the continuous market.

The strategic movement is completed with the increase of shareholding position by Rafael Contreras, member of the Boards of Directors of the biotech company since 2011. Rafael Contreras, in a direct and indirect way, increases his ownership up to 7,5%. Contreras is CEO at Carbures Group and is leading its outperforming international expansion.

As it has been published as Relevant Fact, Victor Infante, CEO and Bionaturis main shareholder, has reduced its participation until 43,06%, as a result of the abovementioned movement. About the operation, Victor Infante has stated: “Bionaturis gains unbeatable conditions to fulfill our growth plan. Their track record in Carbures Group has been impressive”.

The exchanged shares shall keep the original lock-up, held to CEO´s shares.

 

About Carbures

Carbures is an industrial technological group specialized in manufacturing […]

July 8th, 2014|Sin categoría|Comments Off|

Bionaturis Group enhances its international alliances in San Diego (USA)

Bionaturis and BBD Biophenix have taken part in the latest edition of Bio International Convention 2014, in San Diego (June 2014), where the hard-working days have strengthened the international strategies and alliances of the group.

Along three days, the delegates moved to San Diego, Juan Jose Infante (Bionaturis) and Arantza Muriana (BBD Biophenix), has had up to 60 high-level ‘One to One’ meetings, mixing follow-up meetings with already pharmaceutical and veterinarian clients with the evaluation of development opportunities with new ones. The managers of both companies in the Convention have stated: “They have been more than fruitful meetings to consolidate our relationships with current and future partners and to confirm how our join innovative portfolio is at the forefront of the industry, so that we expect to sign new contracts shortly”.

In particular, Bionaturis´ attention has been focused on its portfolio of biological products and the unique features of its FLYLIFE platform as well, whereas BBD has validated the relevance of zebra fish as animal model for increasing the screening success rate not only for the pharmaceutical sector but also for petrochemical, agrochemical, nutraceutical and cosmetics ones.

The Convention in San Diego has also provided a great opportunity to go further within the global expansion plan, with M&As and international growth in Asia and LATAM as  cornerstones.

Expositor

This year Bionaturis Group has participated as exhibitor within the Spanish pavilion, having a booth sponsored by Biobasque. The dynamism shown in this Convention and the record number of partnering meetings is a prove of a wealthy sector with high potential growth. The event showcased the official presentation of Bionaturis Group, after the recent acquisition of BBD Biophenix.

July 4th, 2014|Blog english, Press english|Comments Off|

Bionaturis develops a breakthrough drug for livestock

Bionaturis (ticker BNT-MAB), an international reference company providing biological drugs, has just signed a new collaborative agreement with a multinational company to develop a new product that meets an increasing need of the livestock industry. It is a new first-in-class drug to induce ovulation in livestock prior to artificial insemination.

According to the agreement, Bionaturis will make use of its proprietary system FLYLIFE to develop the product and will also perform efficacy and safety tests in animal models, while the multinational will validate these results in its facilities, performing field trials with the intended specie.

The agreement includes exclusive licensing option rights for the multinational company, which forecasts a minimum potential market of 20-25 USD million for this product.

Victor Infante, Bionaturis’ CEO, commented: “The goal of this collaborative development program is to enable the multinational company to replace the current standard treatment with a safe, cost-effective, scalable recombinant first-in-class solution produced by our technology.”

The new agreement represents another important milestone for Bionaturis in its goal of reaching co-development agreements with large international laboratories and standardize its FLYLIFE platform as reliable alternative system of making cutting-edge medicines.

 

FLYLIFE platform

FLYLIFE is a revolutionary Plug&Play platform designed to produce cost-effective biological drugs at an industrial scale.

Bionaturis offers product licenses, based on its proprietary FLYLIFE platform, providing partners full support for protein therapeutics and vaccines development. 

Bionaturis shares start quoting in the continuous system on the MAB

Shares of Bionaturis (BNT-MB), an international reference company developing biological drugs, will start quoting from next 23 June in the continuous system instead of fixing (with two auctions per day) on the MAB. So that, Bionaturis’ shares will be available to buy and sell at any moment of each trading session.

It´s a new achievement after its recent increase of capital with 76% of oversubscription. Since its opening session on the MAB, BNT shares price has increased 330%, while the liquidity of the value has increased progressively.

According to Victor Infante, Bionaturis’ CEO, “this is a new milestone on our path in response to what investors were asking for. We have confidence that this measure will allow new qualified stakeholders who understand the business and want to make history with us to be on board. Trading by the continuous system means opening the door to specialized investment funds, both national and abroad, that will contribute to consolidate our growth”.

 

Juan Jose Infante: “With Bionaturis, personalized medicine is here”

The unique features of FLYLIFE lead to make personalized medicine a real option. Getting a specific drug to fight a specific disease affecting a region wherever in the world is possible thanks to Bionaturis’ innovative approach. “Pathogens are changing, are mutating, different serotypes of the same bacteria are appearing and because of that, despite having vaccines, people continue getting sick and there are serious health problems in animal farms”, “in the vaccine world in particular and the health sector as a whole the time for ‘One size fits all’ is over. A disease is always slightly different in every single living organism and even it depends on the moment that affects the same organism, so it has to be the solution. It´s not hard to see efficacy rates under 60% of universal solutions in a specific region. Science and innovation are progressing a lot in this sense and more efficacy solutions are in hand but something has to change to these advances getting the patients”  Bionaturis’ CSO, Juan Jose Infante, has said.

As he explains in the following video, Bionaturis’ production platform suits the technological requirements to make cost-efficient medicines for skinny niche populations. To make it a real option and save lives, other non-technological issues have to be addressed.

Here you are the video

June Newsletter

If you want to know Bionaturis’ latest news, here you are our June Newsletter

 

IN THIS ISSUE

Bionaturis acquires BBD BIOPHENIX S. L.
Bionaturis, candidate to the European Small and Midcap Awards
Bionaturis will attend Bio International Convention, in San Diego (June 23-26)

Let’s get to know…

Cristina Peña Guzman, 34 years old, born in Cadiz, Degree at Administration and Business Management at Cadiz University.
 

-When you were a child, what did you want to be as an adult?
A scientist, I was pretty interested in everything related to science, biology, medicine…
-What do you like the most about your job?
Above all, working in a team, but I also like accepting the responsibility of the continuous challenges that appear.
-What are your future challenges?
Carrying on learning every day and doing my best to be at the cutting edge of the needs of the company.
-Your favourite dish
I most like two: my mother’s paella and my husband’s leeks and bacon quiche. In this way none of them gets angry!
-A place
Any Central European city such as Viena or Prague.
-A film
“Shawshank Redemption”, by Frank Darabont.
-A historical figure
Gandhi.
-A book
‘One Hundred Years of Solitude’, by Gabriel Garcia Marquez.
-A song
It’s difficult to choose but I prefer ‘Little Wing’, by Jimi Hendrix, covered by Eric Clapton.
-What do you usually do in your free time?
I spend it with my family. I have a two-year-old son so I haven’t got time to get bored.
-A proposal to get rid of the crisis
Establishing strict limits to everything related to corruption, and encouraging new ideas and projects that will be useful to repackage and find a place in the market.
-How do you imagine the world in 20 years?
With a higher technological level and applied to improve the quality of life of everybody.

  Cristina has been working at […]

June 10th, 2014|Blog english|Comments Off|

Bionaturis, candidate to the European Small and Midcap Awards

Bionaturis is one of the candidates to the well-regarded European Small and Midcap Awards that recognizes and gives more visibility to small and medium size enterprises listing on different European financial markets. In this way it was announced yesterday by the president of Spanish Stock Markets (BME in Spanish), Antonio Zoido, during the MedCap Forum.

In this second edition, Bionaturis competes in the “Rising Star” category, that includes those companies with a market capitalization of up to 50 million. This category awards emerging businesses with clearly demonstrated potential for future growth and healthy increase in share prices.

Bionaturis, listing on the MAB since January 2012, has just fulfilled a capital increase of 3 million euros with 76% oversubscription , has increased its sales 96% in 2013 and it is developing its internationalization plan.

Victor Infante, Bionaturis’ CEO, explains that the nomination to these European awards “supports our business model, that is betting on innovation as driving force and is in the springboard of our international expansion. It provides us more confidence to achieve our goals”.

All nominees will be reviewed by a pre-selection committee, and the 16 companies that best meet the eligibility criteria will be shortlisted. An independent jury composed of members of the financial community, journalists and academia will scrutinizes this shortlist to select this year’s winning companies that most exemplify the many advantages of being a publicly listed company. Last year, two of the winners of these international awards were Spanish Carbures and Gowex. The UK satellite company Veripos was the winner into the “Rising Star” category.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR